Sartorius (OTCMKTS:SARTF – Get Free Report) and ClearPoint Neuro (NASDAQ:CLPT – Get Free Report) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.
Earnings and Valuation
This table compares Sartorius and ClearPoint Neuro”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Sartorius | $3.66 billion | N/A | $90.90 million | $2.15 | 104.65 |
| ClearPoint Neuro | $31.39 million | 12.36 | -$18.91 million | ($0.84) | -16.25 |
Profitability
This table compares Sartorius and ClearPoint Neuro’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Sartorius | 3.82% | 8.19% | 3.15% |
| ClearPoint Neuro | -67.40% | -114.28% | -48.09% |
Analyst Recommendations
This is a summary of recent ratings and price targets for Sartorius and ClearPoint Neuro, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Sartorius | 0 | 1 | 0 | 1 | 3.00 |
| ClearPoint Neuro | 1 | 0 | 3 | 0 | 2.50 |
ClearPoint Neuro has a consensus price target of $19.67, indicating a potential upside of 44.08%. Given ClearPoint Neuro’s higher probable upside, analysts plainly believe ClearPoint Neuro is more favorable than Sartorius.
Insider & Institutional Ownership
30.1% of ClearPoint Neuro shares are held by institutional investors. 6.1% of ClearPoint Neuro shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility & Risk
Sartorius has a beta of 0.98, suggesting that its share price is 2% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 1.01, suggesting that its share price is 1% more volatile than the S&P 500.
Summary
Sartorius beats ClearPoint Neuro on 9 of the 14 factors compared between the two stocks.
About Sartorius
Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services in the United States and internationally. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors, and software apps for bioreactors and cell culture shake flask; fermenters; cell culture media products; cellcelector flex, incubator flowbox, nanowell arrays, and capillaries and tips; fluid management products; microbiology products; and Ultrafiltration membrane filters, glass and quartz microfiber filters, clarification, syringeless and in-line filters, lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, support and services, and live-cell imaging and analysis software; contract manufacturing and integration, membranes and devices, weigh cells, and data analytics, as well as connectivity, and pipetting and dispensing modules; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and biolayer interferometry products. In addition, the company offers water purification systems; surface plasmon resonance; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, equipment manufacturer cells, weights and weight sets, paint mixing solutions, and weighing accessories; and process filtration. Further, the company provides bioprocess consulting and engineering, biologics testing, media and process, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, pharmaceutical quality control, cell and gene therapy, and applied industries. Sartorius Aktiengesellschaft was founded in 1870 and is headquartered in Göttingen, Germany.
About ClearPoint Neuro
ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain. It has license and collaboration agreement with Clinical Laserthermia Systems AB; license and research agreement with Koninklijke Philips N.V., UCB Biopharma SRL, and University of California and San Francisco; and development and license agreement with NE Scientific, LLC. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was incorporated in 1998 and is headquartered in Solana Beach, California.
Receive News & Ratings for Sartorius Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sartorius and related companies with MarketBeat.com's FREE daily email newsletter.
